Last updated 2026-07-27
- Went public on NASDAQ (NRSN), Dec 2021
- Raised $14.2M Follow-on PO, Aug 2025
- Raised $5.7M Follow-on PO, Apr 2023
Total raised
$36.6M
Last: PIPE 2026-04
Stage
Public
Founded
2017
Headcount
16
HQ
Herzliya, Israel
Sector
Health Tech & Life Sciences
About
NeuroSense Therapeutics is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, and Parkinson's disease. The company's strategy is to develop combined therapies targeting multiple pathways associated with these complex diseases. Their lead product candidate, PrimeC, is an oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, designed to treat ALS. PrimeC has received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency for ALS. NeuroSense was founded in 2017 by Alon Ben-Noon.
Funding history · 8 rounds · $36.6M total
2025-08
Follow-on PO
$14.2M
2024-08
Follow-on PO
$2.6M
2023-04
Follow-on PO
$5.7M
2022-07
Follow-on PO
Undisclosed
2021-12
IPO
$12.0M
2020-03
Undisclosed Round
Undisclosed
★ PipelBiz
2020-01
Undisclosed Round
$580K
★ PipelBiz
2019-07
Undisclosed Round
$1.5M
★ PipelBiz
Headcount over time
From 6 (2018-12) to 31 (2025-12) · +25 (+417%) · 16 points · source: Finder history + radar grounding
Q&A
- What is NeuroSense Therapeutics' primary focus?
- NeuroSense Therapeutics is a clinical-stage biotechnology company focused on discovering and developing treatments for severe neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, and Parkinson's disease.
- When was NeuroSense Therapeutics founded?
- NeuroSense Therapeutics was founded in February 2017 by Alon Ben-Noon.
- What is NeuroSense Therapeutics' lead product candidate?
- NeuroSense Therapeutics' lead product candidate is PrimeC, an oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, designed to treat ALS. It has received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency for ALS.
- What was the amount raised in NeuroSense Therapeutics' Public Offering in December 2021?
- In December 2021, NeuroSense Therapeutics raised $12,000,000 in a Public Offering.
- What was the amount raised in NeuroSense Therapeutics' Public Offering in April 2023?
- In April 2023, NeuroSense Therapeutics raised $5,743,677 in a Public Offering.
- What was the amount raised in NeuroSense Therapeutics' Public Offering in August 2024?
- In August 2024, NeuroSense Therapeutics raised $2,556,428 in a Public Offering.
- What was the amount raised in NeuroSense Therapeutics' Public Offering in August 2025?
- In August 2025, NeuroSense Therapeutics raised $14,203,914 in a Public Offering.
- What is the current employee count range for NeuroSense Therapeutics?
- NeuroSense Therapeutics has 11-50 employees.
- What is the total amount of funding raised by NeuroSense Therapeutics to date?
- NeuroSense Therapeutics has raised a total of $24,200,000 to date.
- What is the latest funding event for NeuroSense Therapeutics?
- The latest funding event for NeuroSense Therapeutics was a PIPE round in April 2026, which raised $600,000.
Team · 1
Alon Ben-Noon
Founder · Co-Founder & CEO
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2B
Highlights
1 PatentsVerified
Tags
pharmaceuticalsamyotrophic-lateral-sclerosis-alsdrug-discoverypharma-companiesneurosciencebiotechnologydegenerative-diseasesrare-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | neurosense-tx.com |
|---|---|
| linkedin.com/company/10678539 | |
| facebook.com/neurosensetx | |
| YouTube | youtube.com/channel/UCJU0wswap4MfNS--SCN6s_Q |
Identifiers & details
| Legal name | NeuroSense Therapeutics Ltd. |
|---|---|
| Founded | 2017-2 |
| Employees (exact) | 16 |
| Market cap | $22.8M |
| Status reason | Public on NASDAQ on Dec, 2021; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2021-12 | NASDAQ | NRSN | $12.0M |
Radar intelligence
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515610822 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 2017-02-13 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2023 |
| Active charges / liens | 0 |
| Registry events | 1 — violation (1) |
| Registered address | המנופים 11 הרצליה |
Recent registry events
| Date | Event |
|---|---|
| 2026-05-26 | עדכון הפרה |